Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Sorafekast 200mg Tablet 30's
Manufacturer/Marketed By : APRAZER HEALTHCARE PVT LTD
$20.03 $10.02
Sidmex Inovia offers bulk export supply of Sorafekast 200mg Tablet 30's (SORAFENIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain shipping and...
SORAFENIB
Active Pharmaceutical Ingredient
Sorafekast 200mg Tablet 30's
$20.03
$10.02
Sidmex Inovia offers bulk export supply of Sorafekast 200mg Tablet 30's (SORAFENIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.
Documents, cold-chain shipping and tenders: see our Export FAQ.
Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada
Related products we supply: Sorafekast 200mg Tablet 120's
Sorafekast 200mg Tablet belongs to the group of anti-cancer medicines. The Sorafekast composition contains the active ingredient Sorafenib, which is prescribed for the treatment of advanced renal cell carcinoma (kidney cancer), advanced hepatocellular carcinoma (Sorafekast for liver cancer) in patients who are not eligible for surgery, and differentiated thyroid carcinoma in patients who do not respond to radioactive iodine therapy. The Sorafekast dosage should always be taken as directed by a qualified oncologist. Self-adjustment of dose is not recommended, as it may lead to unwanted side effects or reduced effectiveness. When comparing Sorafenib vs Sorafekast, both contain the same active ingredient (Sorafenib), but differences may exist in terms of brand availability, cost, and formulation. In cases where Sorafekast is not available or suitable, doctors may suggest Sorafekast substitutes depending on the patient’s condition. The Sorafekast price may vary depending on pharmacy, location, and supplier. Patients looking for bulk packs can also check the Sorafekast 200mg Tablet 30's price for cost-effectiveness.
Active Pharmaceutical Ingredient
Uses
• Advanced renal cell carcinoma
• Advanced hepatocellular carcinoma that cannot be surgically treated
• Advanced papillary and follicular Hurtle cell thyroid carcinoma
Benefits
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Sorafekast side effects are
Most Common Side Effects
• Nausea, stomach pain, diarrhea
• Tiredness and weakness
• Infection
• Hair thinning and patchy hair loss
• Rash
• Weight loss
• Loss of appetite
• Low levels of calcium in the blood
• Flu-like illness
Common Side Effects
• Stevens Johnsons Syndrome and toxic epidermal necrosis
• Decreased blood flow to the heart
• Increased risk of bleeding (blood in urine, stool, vomit, cough, etc.)
• High BP
• Skin problems
• Liver problems
• Problems in wound healing
How To Use
Take the Sorafekast tablet without food (1 hour before or 2 hours after a meal). Swallow with a glass of water. Do not break, crush or chew the tablets.
Safety Advice
• Breast Feeding: Do not breastfeed during treatment with Sorafekast Tablet and for two weeks after the last dose. It is vital to let your physician know if you are breastfeeding or planning to breastfeed before starting treatment with this drug.
• Alcohol: Avoid drinking alcohol while taking Sorafekast Tablet as it can cause unpleasant side effects like drowsiness, dizziness, or difficulty in concentrating.
• Liver: Sorafekast tablets should be taken with caution in patients with severe liver disease. Consult your doctor for advice.
• Lungs: Sorafekast tablet should be cautiously administered in patients with certain lung problems. Consult your doctor if you have any lung disorders.
• Driving: This medicine could cause peripheral sensory neuropathy that causes an impact on driving. Hence, avoid driving or doing things that require focus during this treatment period.
• Pregnancy: It is unsafe to use Sorafekast Tablet during pregnancy as it may harm the unborn baby. Inform your physician before starting this treatment if you are pregnant or think you might be pregnant. Your physician will conduct a pregnancy test before prescribing this medicine.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.